Communiqués Kintor Pharmaceutical Limited

Actions

9939

KYG5273B1077

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. Autres places de cotation 07:40:07 24/07/2026			Varia. 5j.	Varia. 1 janv.
1,670 ^HKD	-2,34%		-3,47%	-14,80%

11/06	Kintor Pharma publie des données de sécurité intérimaires positives pour son agent de blanchiment KT-939	MT
10/06	Kintor Pharmaceutical Limited annonce des résultats intermédiaires positifs dans un essai de sécurité à long terme chez l'homme de KT-939 et lance une demande d'enregistrement pour une nouvelle matière première	CI

Communiqués

28/10/23	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
11/10/23	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
28/08/23	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
22/08/23	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
20/07/23	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ
11/05/23	Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	PU
08/05/23	Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China	PU
18/04/23	Kintor Pharmaceutical : Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US	PU
14/04/23	Kintor Pharmaceutical : Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
30/03/23	Kintor Pharma Announces 2022 Annual Results and Recent Business Progress	PR
30/03/23	Kintor Pharmaceutical : Pharma Announces 2022 Annual Results and Recent Business Progress	PU
16/03/23	Kintor Pharmaceutical : Pharma Announces Preclinical Data of GT1708F at AACR 2023	PU
24/11/22	Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use	PU
10/11/22	Kintor Pharmaceutical : Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715	PU
27/10/22	Kintor Pharmaceutical : Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US	PU
16/10/22	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China	PU
29/09/22	Kintor Pharmaceutical : Phase Ib Data of GT0918 for AR+ mBC Published in EJC	PU
30/08/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
29/08/22	Kintor Pharmaceutical : Pharma Announces 2022 Interim Results and Recent Business Highlights	PU
03/08/22	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	PU
27/06/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
15/05/22	Kintor Pharma Included in MSCI China Index	PR
18/04/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
06/04/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
03/04/22	Kintor Pharmaceutical : Pharma Announces Two Upcoming Poster Presentations at AACR 2022	PU